Fate of bone marrow mesenchymal stem cells following the allogeneic transplantation of cartilaginous aggregates into osteochondral defects of rabbits

2010 ◽  
Vol 5 (6) ◽  
pp. 437-443 ◽  
Author(s):  
Tomokazu Yoshioka ◽  
Hajime Mishima ◽  
Zeenia Kaul ◽  
Yoshimi Ohyabu ◽  
Shinsuke Sakai ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2911-2911
Author(s):  
Lynne Margaret van Velzen-Ball ◽  
Katarina Le Blanc ◽  
Arjen C. Lankester ◽  
Helene Roelofs ◽  
Maarten Egeler ◽  
...  

Abstract Graft failure or rejection is an identified problem in haplo-identical or second attempt transplantation. In the bone marrow, mesenchymal stem cells (MSCs) have been identified and shown in animal models to enhance hematopoietic stem cell (HSC) engraftment. Advances in techniques and higher quality culture components have allowed the development of an MSC expansion procedure resulting in sufficient MSCs for clinical application. Adult studies have suggested that co-transplantation of MSCs and HSCs in the HLA-identical setting, is feasible and safe. Here we present the first combined clinical experience within the EBMT MSC expansion consortium with respect to co-transplantation of haplo-identical MSCs in the pediatric allogeneic transplantation setting. Six weeks before the SCT, 50 cc of bone marrow are sampled under sterile conditions. Density gradient-separated MNCs are plated into tissue culture flasks in low-glucose DMEM supplemented with 10% fetal calf serum and incubated at 370C with 5% CO2. At 70% confluence, the cells are trypsinized and re-plated at 4x103 cells/ cm2 until the target dose of 1–2 x106/kg recipient body weight is obtained. Enrichment and expansion of MSCs is performed under GMP conditions in nationally accredited laboratories. MSCs (either fresh or cryopreserved) are administered i.v. 4 hours before infusion of donor HSCs. To date 4 children have undergone co-transplantation. Patient characteristics are summarized in the table. All toxicities associated with the procedure were documented, as were the engraftment kinetics and immune recovery. The study was carried out with approval of the respective local ethical committees. The data indicate that expansion and co-transplantation of MSCs is feasible and well tolerated. While the study is ongoing initial engraftment and immune recovery data (compared to historical data) is encouraging and to date there have been no episodes of graft rejection or severe adverse events related to this treatment. Patient characteristics Patient demographics HSC characteristics MSC characteristics UPN Gender Age Diagnosis Donor CD34 dose (106/kg) Donor Cell dose (106/kg) 1 M 15 ANLL mother-haplo 16 mother 1.5 2 M 2 XLPD father-haplo 20 father 1.9 3 M 2 XLPD father-haplo 18.7 father 1.56 4 M 8 SAA URD (2 loci mismatched) 2.65 mother 1.0





2013 ◽  
Author(s):  
Melo Ocarino Natalia de ◽  
Silvia Silva Santos ◽  
Lorena Rocha ◽  
Juneo Freitas ◽  
Reis Amanda Maria Sena ◽  
...  


2014 ◽  
Author(s):  
Reis Amanda Maria Sena ◽  
Freitas Silva Juneo de ◽  
Silvia Silva Santos ◽  
Rogeria Serakides ◽  
Melo Ocarino Natalia de




2010 ◽  
Vol 29 (6) ◽  
pp. 717-721
Author(s):  
Na SHEN ◽  
Nai-yao CHEN ◽  
Li-kun ZHENG


Sign in / Sign up

Export Citation Format

Share Document